VBLT News and Press, Vascular Biogenics Ltd. From 03/19/20

Vascular Biogenics (NASDAQ: VBLT ): FY GAAP EPS of -$0.54. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020 VB-111 clinical program expands to include U.S. NCI-sponsored study in colon cancer and investigator-sponsored trial in rGBM MOSPD2 progr...

The National Cancer Institute (NCI) has launched a Phase 2 clinical trial evaluating the combination of VBL Therapeutics' ( VBLT +2.6% ) VB-111 (ofranergene obadenovec) and Bristol-Myers Squibb's ( BMY -0.3% ) Opdivo (nivolumab) in patients with metastatic colorectal cancer (CRC). ...

This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, ...

TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced today that Prof. Dror Harats, M.D., Chief Executive Offi...

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in the peer-reviewed jou...

TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented by Timothy Cloughesy, M.D., Director and Professor, UCLA Neuro-Oncology ...

Vascular Biogenics Ltd. (VBLT) Q3 2019 Earnings Conference Call November 12, 2019 10:00 a.m. ET Executives Dror Harats - CEO Amos Ron - CFO Michael Wood - IR, LifeSci Advisors Analysts Geulah Livshits - Chardan Arthur Yu He - H.C. Wainwright Soumit Roy - Jones Trading ...

TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update. “Our OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer is prog...

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a...